Trial Profile
A Phase 1, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Sep 2023
Price :
$35
*
At a glance
- Drugs Rucaparib (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours
- Focus Adverse reactions
- Acronyms RUCA-J
- Sponsors Clovis Oncology [CEASED]; zr pharma
- 16 May 2022 Status changed from active, no longer recruiting to completed.
- 10 Aug 2021 Planned End Date changed from 31 May 2021 to 31 Dec 2022.
- 10 Apr 2021 Results (data cutoff Oct 20, 2020) assessing safety, efficacy and pharmacokinetics of rucaparib in Japanese patients with a previously treated advanced solid tumor, presented at the 112th Annual Meeting of the American Association for Cancer Research.